The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A prospective, nonrandomized phase II/III trial of definitive chemoradiation, with or without cetuximab, in advanced esophageal squamous cell carcinoma.
Yongshun Chen
No relevant relationships to disclose
Jianhua Wang
No relevant relationships to disclose
Xiaoyuan Wu
No relevant relationships to disclose
Chunyu He
No relevant relationships to disclose
Wen Wang
No relevant relationships to disclose
Jinsong Liu
No relevant relationships to disclose
Wei Guo
No relevant relationships to disclose
Bo Tan
No relevant relationships to disclose
Yanxia Wang
No relevant relationships to disclose